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ABSTRACT
The use of broad consent for genomics research raises important
ethical questions for the conduct of genomics research, including
relating to its acceptability to research participants and
comprehension of diﬃcult scientiﬁc concepts. To explore these
and other challenges, we conducted a study using qualitative
methods with participants enrolled in an H3Africa Rheumatic
Heart Disease genomics study (the RHDGen network) in Zambia to
explore their views on broad consent, sample and data sharing
and secondary use. In-depth interviews were conducted with
RHDGen participants (n = 18), study staﬀ (n = 5) and with
individuals who refused to participate (n = 3). In general, broad
consent was seen to be reasonable if reasons for storing the
samples for future research use were disclosed. Some felt that
broad consent should be restricted by specifying planned future
studies and that secondary research should ideally relate to
original disease for which samples were collected. A few
participants felt that broad consent would delay the return of
research results to participants. This study echoes ﬁndings in
other similar studies in other parts of the continent that
suggested that broad consent could be an acceptable consent
model in Africa if careful thought is given to restrictions on re-use.
ARTICLE HISTORY
Received 9 April 2018
Accepted 6 March 2019
KEYWORDS
H3Africa; broad consent;
genomics; bio-banking;
Zambia
Background
Genomics is now a well-established approach to strengthening health research capacity in
Africa, with researchers across the continent engaging in exploring genetic factors that
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play a role in disease causation including how to prevent, diagnose and manage diseases
(Peprah, Xu, Tekola-Ayele, & Royal, 2015; Wonkam & Mayosi, 2014). Such research has
been conducted in conjunction with an evolving understanding of the ethical challenges
that should be considered in its execution (De Vries et al., 2011; Wright, Koornhof,
Adeyemo, & Tiﬃn, 2013). As is the case for health research more broadly, the ethical
topic that has received the most attention is consent, and an increasing number of scholars
have identiﬁed challenges and opportunities for ensuring valid, informed consent for
African genomics research (Tindana & De Vries, 2016). Such literature has described
the diﬃculty of adequately explaining complex genomics research methods (Marshall
et al., 2014; Tekola et al., 2009), the risk of diagnostic misconception particularly when
recruiting healthy population controls (Masiye, Mayosi, & de Vries, 2017) and the
design of consent forms (Munung et al., 2016). Many of the challenges relating to obtain-
ing valid consent for genomics research are rooted directly or indirectly in poverty, includ-
ing for instance participants’ limited access to quality healthcare and low health and
research literacy. But whilst these are features of many participants enrolled in African
genomics research conducted in more rural areas, some evidence from urban Nigeria cau-
tions against making generalised assumptions about prospective participants’ research lit-
eracy (Marshall et al., 2014).
One limitation of the African literature around informed consent for genomics research
is that it reports on ﬁndings from only a limited number of countries, with few papers
reporting on the experiences and views of research participants based in low income
countries in southern Africa. Speciﬁcally, there is no evidence originating from Zambia;
a country which adopted a particularly stringent approach to consent for genomic
research (Chanda-Kapata, Kapata, Moraes, Chongwe, & Munthali, 2015).
One important feature of much genomics research is its reliance on large numbers of
samples to detect small genetic eﬀects. Once collected and stored, there is the possibility
for such samples and data to be reused for valuable research that may or may not be
related to the condition for which they were originally collected. Together, these features
mean that genomics research is often collaborative (De Vries et al., 2011). If samples and
data are to be legitimately available for future research, it is essential that the consent
process at the time of collection allows for this possibility. Where this includes the poten-
tial for research that is valuable but not foreseeable at the time of consent, this suggests the
need for the initial consent to be “broad”.
Broad consent is consent for future studies but with certain restrictions on the nature of
future studies that may be conducted and on the decision processes for allowing future
studies to take place (Grady et al., 2015; Tindana & De Vries, 2016). The use of broad
consent for genomics research raises a number of important ethical questions, including
for instance whether such consent should be seen as ethical considering that even though
future uses are constrained to some extent, people are not given full and speciﬁc infor-
mation about potential studies (Hofmann, 2009). A relatively recent shift in ethics
debates surrounding genomics research has seen greater acceptance of broad consent as
the “best compromise” consent model to be used when recruiting participants (Grady
et al., 2015; Jao et al., 2015; Tindana & De Vries, 2016), possibly because it can be con-
sidered “consent for governance” (Sheehan, 2011). Yet there are pertinent questions
around the use of broad consent for the recruitment of participants for genomics research
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in Africa, relating for instance to the acceptability of such a consent model for research
participants and comprehension of diﬃcult scientiﬁc concepts.
In order to explore these and other issues, we conducted empirical research with a range
of stakeholders to explore their views on the consent process for genomics research
broadly. Our project forms part of a multi-site qualitative study in Ghana, Uganda and
Zambia. In this paper, we report on the results of a study conducted in Zambia where
we conducted interviews with participants (or family members for paediatric patients)
in a genomic study focusing on rheumatic heart disease (RHD). The Genetics of Rheu-
matic Heart Disease (RHDGen) study was conducted under the umbrella of the
H3Africa Consortium (H3Africa Consortium, 2014) and involved research partners in
8 African countries including Zambia. It used a broad consent model seeking consent
for the primary study and for sharing and future use of data. Speciﬁcally, the consent
forms stated that “It is now common that genetic information is shared with researchers
around the world. The beneﬁt is that many researchers can use the same information for
diﬀerent research projects. We would also like to share your genetic information and some
of the clinical information with other researchers for other projects after we ﬁnish our
study. If you participate in this study, you will also need to agree to share your genetic
information for other research in the future.”
RHD is caused by an aberrant immune response to Streptococcus pyogenes throat infec-
tion, and aﬀects mostly children and young adults (Karthikeyan et al., 2012). The con-
dition is strongly poverty-related (Carapetis & Zuhlke, 2011) – whilst virtually
eradicated in wealthy countries and communities, it continues to be a devastating
illness in poor communities in Africa, often resulting in premature death (Zühlke et al.,
2016). It is estimated that RHD could account for up to 1.4 million deaths per year and
is one of the leading non-communicable diseases among children and young adults in
low- and middle-income countries (Carapetis, Steer, Mulholland, & Weber, 2005;
Watkins et al., 2017). Whilst surgical operations are available to replace damaged heart
valves, in Africa such operations are currently only routinely available to public sector
patients in a few countries such as Namibia, Senegal, and South Africa. Zambian patients
do not normally have access to such operations. Genetic risk factors play a considerable
role in the aetiology of RHD (Engel, Stander, Vogel, Adeyemo, &Mayosi, 2011), providing
a strong rationale for conducting large-scale population based genomic studies on this
condition.
Study methods
Study site
The study was conducted at the Department of Paediatrics at the University Teaching
Hospital (UTH) where the Zambian RHDGen study was based. This is a tertiary and refer-
ral hospital for specialised care, based in Lusaka, which is the Zambian capital. Most of the
participants therefore live in urban and peri-urban areas.
Study sample
In this paper, we report on ﬁndings resulting from in-depth interviews with (or family
members of paediatric patients) individuals enrolled in the RHDGen study (n = 18), with
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study staﬀ involved in enrolment (n = 5) and with individuals who refused to participate
(n = 3). We enrolled adult RHD patients, family members of paediatric RHD patients,
and healthy population controls approximately one year after they consented to partici-
pate in the RHDGen study. Table 1 gives an overview of these participants. We identiﬁed
patients using a register of participants in the RHD study. We contacted patients by tele-
phone. In addition to the interviews reported in this paper, we also conducted 20 inter-
views with regulators, researchers and ethics committee members, but we report on the
results from that component of our research elsewhere. Due to delays in obtaining ethics
approval for this study, we started recruitment for this study when the RHDGen study
had already completed enrolment. This means that we spoke with our interviewees
sometime after they had agreed or refused to participate. The timespan between the
date of RHDGen enrolment and the date of the interview ranged anywhere from 10
months to 20 months. When enrolling people at this study, we explained the concept
of broad consent to interviewees when administering informed consent and during
the interviews. Our explanation included the diﬀerence between broad consent and
blanket consent by emphasising that blanket consent does not restrict the use of
future use of samples while broad consent does. Broad consent was also distinguished
from speciﬁc consent by indicating that the latter is concerned with the particular
study for which samples and data are collected. Interviews with RHDGen participants
and non-participants were conducted in Nyanja (n = 15), Bemba (n = 3), Tonga (n = 1)
and English (n = 2) and translated to English. All interviews with staﬀ were conducted
in English.
Data analysis
All interviews were audio-recorded and transcribed verbatim. Where interviews were not
conducted in English, they were translated simultaneously by two research assistants and
we veriﬁed the translation independently. Following transcription, text ﬁles were imported
into NVivo 11 (QSR International Pty Ltd, 2015). This involved initial open coding of 5
transcripts by two researchers (OM and JdV). Following discussion, we developed a hier-
archical coding scheme together with a codebook describing each code and its relationship
to overarching study themes. Interviews were then coded by the researchers and two
research assistants. Two researchers (OM and JDV) together analysed and interpreted
coded data using the Framework Method functionality embedded in NVivo 11 (Gale,
Heath, Cameron, Rashid, & Redwood, 2013; Parkinson, Eatough, Holmes, Stapley, &
Midgley, 2016; Smith & Firth, 2011). We discussed data interpretations with the wider
study team.
Table 1. Number and type of interviewees recruited.
Type of interviewee Enrolled in RHDGen? Number
Study staﬀ No 5
Family member of paediatric RHD patient No, but consented
to enrol their child
4 (2M, 1F plus an interview
with both parents present)
Adult RHD Patient Yes 4 total (4F)
Healthy control, unrelated to RHD patients Yes 4 total (3M, 1F)
Healthy control, related to RHD patient Yes 1 total (1F)
Individuals who refused to participate No 3 total (1M, 2F)
Note: F = female; M =male.
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Findings
This study set out to explore Zambian RHDGen participants’ views on one model for con-
senting used in genomics research called broad consent. A number of inter-related themes on
broad consent emerged from the interviews. These include views on broad consent; sample
and data sharing and bio-banking; consent for research on the stored specimen for which
broad consent was not obtained; concerns about blood collection and use; and motivation
to participate in the RHDGen study and feedback of ﬁndings. Table 2 summarises the key
ﬁndings on each of these themes.
Views on broad consent
In general, most participants seemed to have a positive view of broad consent on condition
that information on the reasons for storing the samples for future research use was dis-
closed. Most participants were able to relate broad consent to what they remembered
about the RHDGen study. The participants including one of those who opted not to par-
ticipate in the RHDGen study, remembered quite a lot of detail about the RHDGen study
including that RHD aﬀected the valves of the heart, and that the RHDGen study aimed to
establish the genetic causes of RHD which involved the exporting and keeping of samples
for a long time. They also indicated that they were told that feedback of study results would
take long.
Several participants also argued that if the research participant is informed from the
onset when the sample is being collected that researchers plan to use the specimen for
other research in future, they would not have a problem with that. One participant argued:
[broad consent] is acceptable when that person is counselled; then that person can be con-
vinced and accept but if they refuse that’s up to them as an individual but ﬁrst, start with
counselling, you are counselled you are told so that you know what you have gone there
for … it is up to me to accept or refuse. (IDI 11 – Female unrelated control)
Importantly, some participants felt that broad consent should be restricted in a way
such that the planned future research should be spelled out and should not deviate so
much from the original research the participant consented to. One participant argued
that further research should only be permitted if it helps to understand the original
health condition of the patient who gave the sample.
When you are talking about broad consent and if declaration is made at that point then if I
have allowed you to go ahead then you may go ahead with that… but I still feel that the con-
centration really should be more of what aﬀects the person that you got the sample from,
should be the main focus… I think it is good to stick to what the [original] research is all
about but if the other researches are helping to understand more, then there is nothing
wrong with that. (IDI 5 – Adult female patient)
Yet other participants were uncomfortable with broad consent because they felt it
would delay the return of research results to participants – which would indicate some
sense of therapeutic misconception.
Broad consent is not a good idea, when they collect blood, they need to give us results there
and then so that if there is need to oﬀer help, they do it fast. There are a lot of diseases found
in the blood like hepatitis, diabetes, heart disease and many others. But if that blood is going
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to [other countries], they would not help us fast enough. In fact, what we want us people with
heart problems is that there should be quick treatment. (IDI 8 – Adult female patient)
The therapeutic misconception was not only limited to those who chose to participate
in the RHDGen study. One participant who opted not to participate in the
RHDGen study gave as the main reason for not participating, that their son was getting
better; and hence that there was no need to participate in the research. Here is an exchange
between the interviewer and one of the respondents who declined to participate in the
RHDGen study.
Interviewer: I want to know, how much understanding did you have about the study?
Respondent: I think I understood it well and we wanted to participate, I was with my
husband, he also agreed but because our son was getting better so he [husband] did not
see the need to participate in research, because he [our son] was improving.
Sample and data sharing, and bio-banking
As indicated above, the notion of broad consent has primarily been developed in relation
to the requirement for the storage and sharing of samples and data in collaborative geno-
mics research. In principle, most of our interviewees supported the sharing of samples and
data among researchers. There were some variations and similarities on the reasons
advanced for supporting sample sharing and data sharing. For example, some participants
supported both sample and data sharing because they thought this would improve the
likelihood that researchers could learn something that beneﬁts the patients and the com-
munity at large.
…we want to know where the disease is coming from. So if they get the sample and have
shared, it is just okay because we are want to ﬁnd out what is bringing the diseases …
that is what is important to discover the diseases to help other people and the person you
got the sample from. (IDI 4 – Male parent)
One highly educated participant (with tertiary education) also argued that sharing
samples and data increases the sample size for research which increases the power of
the study conducted from such samples and data, hence improving the reliability and val-
idity of the study and producing results that will beneﬁt patients and generally health care.
You see when you are doing research, I always believe in a wider range of samples to try and
get the true picture… So, to narrow the percentage error, it is good to share the samples to
come up with realistic results because I believe that you are doing this to try and ﬁnd sol-
utions to many people that are suﬀering out there, and come up with the best medications.
(IDI 5 – Adult female patient)
There were also some participants who did not mind their samples and data being
shared as long as this was done in an anonymised form.
Like you have said you don’t put names; you don’t put anything for you to identify who the
blood belongs to; it is ok because other scientist will not know that it’s us. (IDI 15 – Female
parent related control)
Others did not have problems with sample sharing because they related it to giving
blood donations, which was in their mind routine and “normal” as a way of saving
other people’s lives.
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On bio-banking, most participants felt that it was a good idea because it would provide
an opportunity to use the samples to conduct research that will ﬁnd solutions to medical
problems and diseases.
It is not a bad thing because you ﬁnd that when you look at this critically, even when there is a
new disease, for them to ﬁnd medicine, some people would have died, sometimes they could
have gotten samples from those people, and they go do research to ﬁnd a cure for that disease.
So on that issue where they get blood samples and they keep them for three to four months it
is not a bad thing because even those who come to learn from the samples, they are the ones
who are helping us. (IDI 13)
Some participants also felt that biobanks would provide an opportunity or resource for
training “future” scientists and students. Two participants put it this way:
Biobanks, I think it is a right idea, specimens are stored in a safe and in good condition. Many
students coming by will learn, do research and deﬁnitely they will ﬁnd an answer, one day
they deﬁnitely ﬁnd an answer. It is a very good idea. (IDI 12)
On banking that blood you got for others to investigate and learn from it; I see it as a good
idea because our children will learn from that blood you are storing in there, there are chil-
dren who are still going to school, those children coming in the next generation, you will
teach them using the same blood rather than throwing it away… if you store it, it’s good
it will help us. (IDI 15)
Consent for research on stored specimens for which broad consent was not
obtained
The participants also discussed ways to approve or monitor future research on existing
archived specimens originally collected from participants for a diﬀerent purpose with
speciﬁc consent. Most participants argued that they would prefer that the researcher
informs and re-consents the participants who provided the sample. However, some par-
ticipants argued that regulatory institutions such as ethics committees and holders of
specimens such as researchers should review and approve such research especially when
it is diﬃcult to trace the participants who gave the specimen.
[If] am not here and I have given you my samples, I stay far, and you are in a diﬀerent place
… I think it just okay for you just get the sample and learn from them and maybe from the
place where that sample is kept you can get the permission from them because on my part
you already got the samples from me. (IDI 4 – Male parent)
There was one participant who thought that research should be allowed to go ahead
even without consent as along as it beneﬁts society and the individual concerned stand
to beneﬁt from such research.
They can just learn from them [samples] because still there are kids that will be getting sick. It
is not just our [daughter], the other children that can get sick, many people are sick and a lot
are still coming because this is the condition [RHD]. (IDI 2 – R2 – Female parent)
Another participant felt that they had no control on the specimen that is already given
because it is already in the hands of the researcher.
Since they have them already, even if we say that we deny, they may use them. There is no
way we can object because they have the samples already. (IDI 2 – R1 – male parent)
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Concerns about blood collection and use
Blood is a common specimen used and shared in genomics research. Many of the partici-
pants in this study expressed concerns about the blood collected for the RHDGen study,
which relates directly to their views on sample storage and sharing. The general concern
was that blood may be abused for satanic rituals especially when given or shared with
researchers who are not “known” (not Zambian) to participants. If shared with
unknown researchers, some participants argued that they would not know how the
blood samples would be used and would have no control over what can be done. The
absence of trust and control leaves room for abuse.
Other people they are not comfortable. You know why, because people are scared in this
world we are living in, blood samples are used for so many diﬀerent aspects, not only
medical purposes. [so] other people it was not easy to just give blood. The researchers had
a tough time to convince them because people don’t just give blood anyhow because it
can be used for wrong purposes. (IDI 12 – male unrelated control)
These concerns about blood were also used by potential participants to discourage
others from participation.
We were discouraged to say when you give too much blood you faint, others said that your
blood will be taken into Satanism. So for me I said “no, even if it’s Satanism for us we want to
give blood to help people”. (IDI 14 – male unrelated control)
The participants argued that this view was not limited to research participants but was
common in the community. This includes some churches, who participants described
forbids the giving of blood for fear of it being used for satanic rituals. There are also
some participants who were concerned that researchers may be selling the blood for
proﬁt while one participant was worried about fainting due to loss of blood.
Most of these concerns about blood were echoed by staﬀ involved in the recruitment of
participants in the RHDGen study. They indicated that concerns on how the blood will be
used were the main reason potential participants declined to participate in the study. The
staﬀ indicated that both those who refused to join the study and those who joined were
uncomfortable that their blood was to be shipped to other countries, which may
explain why so many participants remembered this particular aspect of the RHDGen
study.
Yet even amidst rumours of Satanism, because of the severity of the condition, one
parent expressed determination to participate in the study, hoping to ﬁnd a solution to
the condition of their daughter.
These are the things people are saying for sure [discouraging to donate blood for fear of
Satanism] but for us we want our child to get better even if they discourage us we are just
looking for solution our child… So I said the Satanism didn’t matter to me, what mattered
was to ﬁnd the cause of the problem [RHD]; if it’s with us the parents [genetic] or if the
problem came on its own. (IDI 15 – Female parent related control)
Motivation to participate in the RHDGen study and feedback of ﬁndings
All participants were aware that study participation was voluntary and many participants
indicated that they participated in the study because of the potential beneﬁts that may
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come with the study. Motivations for participating in the study varied between those who
were patients or parents of children with RHD and healthy participants. Those who were
(parents of) patients hoped that through the study they would facilitate access to specialist
and advanced treatment for their condition. Those who participated as healthy controls
saw participation as an opportunity to know how healthy their heart was because the
study involved a detailed examination of the heart and free medical consultation with
heart specialists if any abnormalities were found.
Yet against this background of expecting a personal beneﬁt, many participants also
described altruistic reasons for participating, often linking these to descriptions about
the devastating nature of RHD for children and expressing the hope that participation
would help researchers learn more about the causes of this illness as well as developing
new treatments for future generations.
Table 2. Emerging themes.
Theme Key ﬁndings
Views on broad consent . Positive view of broad consent if the participant suﬃciently
informed
. General feeling was that broad consent should be restricted only
to future studies that help understand the outcomes of the original
study and the health condition of participants
. Some people were sceptical about broad consent because it meant
that the return of results would take long
Sample and data sharing, and bio-banking. . Sample and data sharing supported if it ultimately beneﬁts the
patients and community at large
. Sample and data sharing supported if it increased the power,
validity and reliability of the study
. Sample and data sharing supported if the samples are anonymised
Consent for research on stored specimens for
which broad consent was not obtained
. Researchers should inform and get consent from participants who
provided the samples
. If impossible to contact participants, regulatory institutions can
review proposed studies and approve
. Research can go ahead if it beneﬁts the society and individuals
who gave the sample
. Participants have no control on samples once given
Concerns about blood collection and use . Fear that blood will be used for satanic rituals when shared with
unknown (foreign) researchers
. Not sure how the blood will be used because they have no control
once the blood is given
. Fear that blood will be sold for proﬁt
. Worry about loss of blood
Motivation to participate in the RHDGen study
and Feedback of ﬁndings
. Participation will help understand the causes RHD condition and
ﬁnd solutions to the management and treatment of the condition
access to specialist treatment and surgery
. Participation provided an opportunity for free screening and
diagnosis for heart conditions
. Participation created a network for sharing experiences among
RHD patients and care givers
. Participants keen to know the results including individual genetic
test results and other incidental ﬁndings relating to participants’
health
. Feedback on general results will maintain trust and promote future
recruitment of study participants
. Feedback of results could explain the RHD condition and how to
manage it in future
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One unexpected inﬂuence of the RHDGen study is that it led to the creation of a
support network of patients where they are able to share experiences about the RHD con-
dition and best ways to manage and cope with the illness.
We talk about these things when we meet, it’s like we become one family and we know each
other. So we are happy that the research you are doing, you should continue investigating to
ﬁnd out the cause of the problem and then a solution can be found… (IDI 15 – Female
parent related control)
This social network extended to the staﬀ on the RHDGen study. The lead staﬀmember
reported how the relationship with the participants especially RHD patients and their
parents evolved over the course of the study to a level where they continued consulting
each other and seeking comfort. She indicated that patients have remained “attached”
to her and other research staﬀ and continue to hope that the RHDGen study would
provide solutions to their plight.
Because of the shared experiences with the RHDGen study and expected health beneﬁts
that motivated participants to join the RHD study, almost all participants were keen to
know the study results and thought that feedback should include results of the genetic
tests for individuals who participated in the study. Here is how one participant put it.
Of course these samples were going far; it’s not near and a number of test were going to be
done to try and establish, so when I heard that, I was interested to say I might get some infor-
mation on how I found myself like this [with RHD]…Actually, am looking forward to hear
what the outcome is. And if there any recommendations on how I should live after that? [The
research staﬀ] mentioned that in future they will get in touch with me but it has been quiet.
(IDI 05 – Adult female patient)
Whilst all participants describe their expectation that they would receive some results,
only three spoke about receiving general study feedback (in conjunction with individual-
level results) and the others only spoke about receiving individual research results. With
regards to receiving general study ﬁndings, participants articulated the view that feeding
back such ﬁndings would be a matter of courtesy and would play a role in maintaining
trust, which could promote future recruitment of study participants.
For us guys who volunteered, its best that you get back to us and tell us more because we are
interested, that is why we volunteered, so it is best that you come back to us, even sensitise us
more so that we can feel we are part of this research. (IDI 12 Male Unrelated Control)
With regards to the return of individual research results, participants expect results that
pertain directly to RHD, as well as information pertaining to other conditions found in
their blood. When probed, this includes information about other conditions such as dia-
betes and HIV.
Respondent: When the results come out, I would want to be told what have been found in the
child [patient].
Interviewer: So if you gave the sample for testing for the heart, and they test for example dia-
betes would you want to know?
Respondent: Yes, I would want to know (IDI 03 Female Parent)
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Participants described an obligation on the part of researchers to inform them of any
pertinent results identiﬁed in the project if these are relevant to their health.
I think that since you are the only one who knows that this blood belongs to Agnes’mum that
has such a problem, you are supposed to call me and ﬁnd a way to prevent it. (IDI 15 Female
Related Control. “Agnes” is a pseudonym)
One challenge is that the recruiters used the family inheritance analogy to explain the
genetic component of our study – and as we showed above, many participants remem-
bered this component of the RHDGen study. But this explanation may also have confused
participants, in that they understood that the study was aiming to understand why they or
their children developed RHD.
I did understand what they said, to know where the problem for Alex is coming from. (IDI 02
Parents of paediatric RHD patient themselves enrolled as related controls. Alex is a
pseudonym)
People expect feedback for a number of reasons, including an expectation that it would
reveal information about why their condition developed and how it could be managed in
the future.
Yes, the results delay to come back and they don’t let us no know the results from the blood
samples they got and what the way forward will be. (IDI 08 Adult female patient)
The staﬀ who recruited the participants for the RHDGen study conﬁrmed partici-
pants’ desire to know their results. They argued that participants, particularly those
with RHD or parents of children with RHD were desperate for solutions to their con-
dition and hence needed immediate feedback on their results. The hope from the par-
ticipants is that knowing the results may help ﬁnd solutions to their condition. This was
despite explaining to the participants that they should not expect individual beneﬁt and
that the study would take long to complete. The lead nurse on the team added that she
continued receiving calls from participants wanting to know their results, one year after
the study closed.
Sadly, by the time we conducted the interviews, three of the paediatric patients who had
enrolled in RHDGen had passed away, illustrating how deadly this disease is in the absence
of heart valve replacement operations. The family members of those children expressed a
desire to receive results that may help them understand more about the condition in
general, and about whether anything could have been done to prevent the death of
their child. Understandably, they also expressed frustration with the researchers and
their institutions that the results they were expecting were not given “more quickly”.
That’s what kept coming to my mind, but I never just wanted to show it. I was just trying to
calm down to say just wait, the results will come out but all in all, what we wanted is the atten-
tion to the boy; it was supposed to come because those researches whatever you were doing,
to me, it was taking time for those results to come out and to be communicated to the
involved people. (IDI 01 Family member of deceased RHD patient)
I have noticed that from the time they collected blood samples, it could have been good if the
results were out and that main problem known before she even died, maybe something could
have been done. (IDI 07 Female Parent to deceased RHD patient)
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Whilst in international debates around the return of individual genetic research results
emphasis has been placed on autonomy as a guiding principle to determine whether
results should be fed back, our participants all seemed to be of the opinion that individual
results pertinent to the health of the participant ought to be fed back. The reason for this,
seemingly, is an expectation of reciprocity – that it is part of the researchers’ duty to care
broadly for the health of research participants, and to “help” them if they can. One respon-
dent who refused to participate in the RHDGen study emphasised that participants in
genomics research should beneﬁt from it as much as the researchers do.
Let’s say you are studying the RHD, you ﬁnd the cure for RHD, there will be money involved
in that, so those people who will be making those medicine will be selling to the entire world
and make a lot of proﬁt. The person who contributed blood is not getting anything and is not
even remembered… Researchers must not forget the contributor of the blood because they
are taking part of their life, they are giving you [researchers], for someone else to beneﬁt.
Discussion
In general, participants in this study found the use of broad consent reasonable if it is
clearly explained to them at the onset of the study. By that, participants seemed to
mean that the intention to store and share samples and data for future studies should
be clearly explained to and understood by participants before signing the consent form.
These ﬁndings are consistent with other studies. For example, in a study based on a
review of the literature on broad consent in the context of genomics and bio-banking
research, Tindana and De Vries (2016) found broad consent and sharing of samples
and data to be acceptable in diﬀerent contexts in low- and middle-income countries.
However, our study went further to reveal that acceptability of broad consent may be
contextual to participants’ health problems and speciﬁc needs. For example, our study
shows that one frequently given reason for supporting broad consent and sample and
data sharing was the hope that this would accelerate knowledge generation and the devel-
opment of new treatments for Rheumatic Heart Disease, for themselves and others. Such
expectations were linked to the reported gravity of the condition – in our group of 11 RHD
patients, 3 children who had enrolled in the RHDGen study a year previously had since
passed away – and the very costly treatment options available to participants. In the
light of such a lethal and largely untreatable condition in the Zambian context, partici-
pants expressed support for anything and everything that could help alleviate their
plight, and that of others.
As indicated earlier, broad consent is not open-ended or “blanket” consent, but rather
consent for future use with restrictions (Grady et al., 2015; Tindana & De Vries, 2016). In
the literature, it is not currently clear what level of restrictions would be acceptable for
African research participants. Arising out of concerns of sample misuse as well as con-
siderations of fairness, most participants suggested that future studies should be limited
to the condition for which samples were collected. They also suggested that there
should be concrete ways to ensure that any beneﬁts from future studies would trickle
back to participants, other patients with RHD, or Zambia. This was true for generic
study ﬁndings and possible treatments, but also for individual study results including indi-
vidual genetic ﬁndings. This resonates with other studies conducted on the continent. For
instance, van Schalkwyk, de Vries, and Moodley (2012) also found that participants
12 O. MWEEMBA ET AL.
supported re-use that was beneﬁcial to others in their immediate environment. Jao et al.
also found that participants in Kenya considered broad consent as the “best compromise”
to balance scientiﬁc utility with ethical principles, but with the requirement that future
studies are of beneﬁt to their communities.
On some level, participants seemed to talk about the feedback of individual research
results as a proxy to reciprocity – or, as part of the expectation that researchers will be
cognisant of and seek to alleviate their poverty and medical needs insofar as possible.
Some of the participants we recruited are too poor to aﬀord even the most basic forms
of medication or medical consultation. They do not have access to heart operations that
would make their conditions manageable. Against this background, participants empha-
sised the importance that researchers think carefully about how their project can accom-
modate patient needs, for instance through feeding back pertinent information that would
help them access better treatment or plan their lives. One important implication is that
African genomics research projects need to develop a clear protocol and counselling strat-
egy for participants including a plan for disclosure where results have implications for the
family or community.
It was also clear from our study that participants struggled to separate the research
healthcare components of the RHDGen study, possibly because the study’s primary inves-
tigator was also the treating cardiologist for many participants. For example, with regards to
the return of research results, we found strong evidence of diagnostic and therapeutic mis-
conception, which is the belief that blood samples collected for genomic research are actually
taken for diagnostic or treatment purposes (Masiye et al., 2017).Whilst Masiye et al. describe
diagnostic misconception in healthy participants enrolled as controls, in this study we ﬁnd
this misconception to equally exist with RHD patients and their family members.
The ﬁndings from this study add to the body of knowledge for developing evidence-based
legal and regulatory frameworks in genomics research in Africa. For example, in Zambia, the
2013 Health Research Act (HRA) prohibits the use of broad consent by prescribing that
consent needs to be speciﬁc and may not be obtained for unspeciﬁed future studies
(Chanda-Kapata et al., 2015; de Vries et al., 2017). Whilst the HRA was partly developed
to protect participants from exploitation, this study raises a debate on whether the assump-
tions that informed the development of the HRA are grounded in the views of diﬀerent sta-
keholders especially as far the use of broad consent for genomics research is concerned (Jao
et al., 2015). This suggests that more research is needed on the views of diﬀerent stakeholders
on the use of broad consent in genomics and bio-banking research in Zambia.
Our study is limited is two ways. Firstly, due to the time lag between the time the
RHDGen study was implemented and the time we conducted our interviews, the partici-
pants were only telling us what they remembered about the study and there may have been
some recall bias. We considered this in our study by focusing the interviews more on
hypothetical questions relating to sample and data sharing that were not speciﬁcally
linked to the RHDGen study. However, despite the time lag, almost all interviewees
remembered enrolling in a research study exploring heart disease; that many described
that the study related to inheritance or genetics of this condition; and that many recalled
that samples were sent to South Africa. Secondly, most interviews were not conducted in
English but in Bemba and Nyanja. This required, ﬁrst, the translation of study materials
(consent forms, topic guides) into these languages, and then the translation of recordings
and transcripts into English. It also required the researchers conducting interviews to
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consider how to best describe pertinent terms and concepts in these languages. Several
authors have described how diﬃcult it is to eﬀectively communicate about genomics
research in African languages that lack terms for scientiﬁc concepts such as “genes”,
“DNA”, “data sharing”, “bio-banking” and so forth (see for instance Tindana & De
Vries, 2016; Tindana et al., 2012). We sought to be mindful of this challenge by not
over-interpreting participants’ views, and by exploring the initial recording if we had ques-
tions about the accuracy of the translation.
Overall, our study contributes to the existing literature on broad consent in the context
of genomics and bio-banking research. In particular, our study adds to the consensus that
broad consent could be permissible and possible in African research settings, if explained
well to participants, and if used in conjunction with restrictions on future use. It also adds
to the debate on how broad consent is complicated in contexts where there are reciprocal
interests by researchers and participants especially when participants are desperate for sol-
utions to their medical problems. Lastly, it contributes to the debates on the appropriate
regulations and legal framework for genomics and bio-banking research in Africa.
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